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Abstract: Onychomycosis is an increasingly common fungal nail infection, chiefly caused by
dermatophyte fungi. The disease is notoriously difficult to treat due to the deep-seated nature of
fungi within the nail plate, prolonged treatment requirements, poor patient adherence and frequent
recurrences. Given the poor efficacy of currently available topical and systemic therapies, there is a
renewed interest in exploring alternative treatment modalities for onychomycosis. Natural therapies,
physical treatments and various combination therapies have all shown potential for the management
of onychomycosis, though research on many of these methods is still in preliminary stages.
Further large, well-designed, randomised controlled trials are necessary to confirm the efficacy
of these novel treatments in order to make formal recommendations regarding their use in the
management of onychomycosis.
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1. Onychomycosis and Associated Risks
Onychomycosis is a common fungal nail infection that has been estimated to account for about
half of all nail diseases [1]. Although not life threatening, fungal nail infections are an important
public health concern due to their high prevalence, poor response to therapy and significant clinical,
social and financial impact. Risk factors for the development of onychomycosis include advancing
age [2], the presence of nail trauma or psoriasis, wearing occlusive footwear, participating in sporting
activities like running or swimming, and a history of fungal infection elsewhere on the body [3–5].
A rise in the prevalence of onychomycosis over the past few decades has been attributed to a number
of causes including an increase in the number of immunocompromised individuals (including people
with diabetes) [6], longer life expectancies, increased urbanisation, and use of occlusive modern
footwear [7].
Fungal infections are contagious. They can be transmitted to others via direct skin-to-skin contact,
but are more often spread through shedding of infected dead skin/nail cells and fomites contaminated
with fungal propagules [8]. The secondary spread of fungal organisms within the same individual can
lead to the infection of other nails, web spaces, toes and potentially the whole foot. If left untreated,
the infection can act as a reservoir for other skin conditions, including atopic dermatitis, urticaria and
erythema nodosum, as well as fungal infections in other parts of the body. Onychomycosis can
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also exacerbate foot problems resulting from other illnesses like diabetes, and in extreme cases can
ultimately necessitate lower extremity amputation [9].
2. Current Treatments
While the range of emerging treatments against onychomycosis is rapidly expanding, most current
treatments still fall under either topical agents applied directly to the nails or systemic agents taken
orally (Figure 1). Treatment selection depends on the extent and severity of nail changes, the organism
responsible, concerns about drug interactions or adverse effects, and success or failure of previous
treatments [10]. The severity of infection is assessed based on the extent of nail involvement, degree of
nail discolouration and nail plate thickening, onycholysis (separation of nail from nail bed) and pain.
 
Negative 
culture/Biopsy 
Symptomatic treatment of nail 
dystrophy and infection 
Oral medications: first-line 
therapy for moderate–severe 
onychomycosis 
Terbinafine 
Child <20 kg: 62.5 mg/d 
Child 20–40 kg: 125 mg/d 
Adult: 250 mg/d 
Up to 6 wks for finger-
nails and 12 wks or more 
for toenails 
Itraconazole 
Standard treatment: 
200 mg/d × 12 wks 
Pulse treatment: 200 mg 
twice-daily × 1 wk/month 
× 2 pulses (fingernails) or 
3 pulses (toenails) 
Fluconazole 
150-300 mg/wk × 12–
48 wks 
Tavaborole 
Once daily × 48 
wks 
No removal of 
dead, damaged 
or infected tissue 
required 
Patient presents to a healthcare setting 
Positive culture/biopsy 
of nail specimen 
Clinical examination and 
diagnosis 
Topical therapy: for mild–
moderate cases of distal or 
superficial onychomycosis 
Amorolfine 
Once weekly × 48 
wks 
File down 
infected nails 
once a week 
Ciclopirox 
Once daily × 48 
wks 
Clip or file down 
infected nails 
once a week 
Efinaconazole 
Once daily × 48 
wks 
No removal of 
dead, damaged 
or infected tissue 
required 
Laser therapy: to 
temporarily increase the 
amount of clear nail 
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of nail specimen 
(mycological cure) 
Prophylactic treatment 
Patient education to 
prevent recurrence 
Positive culture/biopsy 
of nail specimen 
Combination therapy 
Mechanical therapy 
Chemical treatment 
Treatment 
follow up 
Figure 1. Onychomycosis treatment algorithm (modified from Thomas et al. [4]).
Topical treatments (like amorolfine and ciclopirox) are used for managing minor infections of the
nail plate. While topical antifungals have the advantage of causing fewer and less serious side effects,
treatment periods are long, and efficacy is limited due to poor nail plate penetration. Clinical trials
have shown newer topical agents like efinaconazole 10% and tavaborole 5% to be significantly superior
to placebo [11,12]. However, further comparative trials are required to determine their relative clinical
efficacy and provide more effective recommendations for patients.
Oral antifungals (like terbinafine, itraconazole and fluconazole) are required for most cases of
onychomycosis because of their greater ability to penetrate the nail bed and nail plate. Common
side effects of these medications include headaches, gastrointestinal symptoms, nausea and rash [13].
Furthermore, health professionals must be cautious of dangerous drug–drug interactions and increased
risk of hepatotoxicity [14]. Terbinafine is currently the preferred oral treatment against onychomycosis,
with recent reviews and meta-analyses showing it to be more effective than other treatments [13,15].
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3. Treatment Challenges
Onychomycosis is notoriously difficult to treat. Achieving complete cure can take as long as
18 months [16] and cure is not achieved at all in 20–25% of treated patients [17]. Furthermore,
the disease is associated with very high recurrence rates due to the presence of residual fungal spores
or hyphae, with relapse occurring in 6.5–53% of patients [18]. The efficacy of current treatments is
limited by the slow growth of toenails, nail keratin thickness preventing penetration of topical and
systemic drugs, and survival of fungi in surrounding environments (such as footwear) for long periods.
Because of their lack of intrinsic immune function and impenetrable nature, nails are a particularly
challenging tissue to cure [19]. Individuals with onychomycosis can experience very long-lasting
disease, especially in the absence of effective treatment. An average disease duration of almost 18 years
was recorded among 2761 onychomycosis patients in Poland [20].
Recent microbiological advances suggest that fungi, like bacteria, are able to form biofilms,
complex sessile microbial communities permanently attached to epithelial surfaces in an extracellular
matrix. The presence of a protective barrier created by fungal biofilms may partly explain the high
rates of treatment failure, recurrence and relapse seen in onychomycosis [16]. For this reason, it has
been suggested that antifungal agents should be tested for effectiveness against fungal biofilms and
not exclusively planktonic cells [16].
Susceptibility to onychomycosis increases with the presence of other underlying comorbidities,
including chronic renal failure (with dialysis) and renal transplant, immunodeficiency, diabetes,
cancer and peripheral arterial disease [3,6]. These comorbidities and associated polypharmacy make
some patients ineligible for oral antifungals. Furthermore, systemic side effects associated with
oral antifungals can lead to patient nonadherence and treatment failure. To address these issues,
new treatment methods are being investigated for onychomycosis that can avoid the pitfalls of
standard systemic and topical therapies. Natural therapies, physical treatments like photodynamic
therapy [21] and laser therapy [22], and various combination therapies are among treatment avenues
currently being explored by researchers and clinicians to improve cure rates in onychomycosis.
4. Natural Therapies
Given the challenges associated with available topical and systemic agents, there is a renewed
interest in exploring alternative natural treatments for onychomycosis [19]. Natural onychomycosis
therapies may have some important advantages over current treatments. They have the potential
to be less expensive, particularly if classified as over-the-counter or complementary medications.
Furthermore, they have shown low levels of adverse reactions in human trials (mostly skin irritation
or mild pain) (Table 1), suggesting that these medications could be safer and more tolerable than
standard therapies. Because of the complex nature and composition of bioactive constituents present
in plant-based treatments, natural treatment modalities may carry a lower risk for the development
of fungal resistance [23]. These qualities indicate potential for natural therapies to be employed as
prophylactic agents against onychomycosis.
While a number of natural remedies have shown promising antifungal activity in vitro,
clinical trials on these treatments are as yet in early stages. For example, essential oils like tea
tree oil have demonstrated antifungal activity in vitro [24,25], but their efficacy has not been
adequately confirmed against onychomycosis in human trials [26] (Table 1). Most human trials
investigating natural therapies for onychomycosis have been small-scale pilot studies that are not
directly comparable with trials on standard treatments due to differences in design and methodology.
A six-month clinical trial investigated Ageratina pichinchensis (AP), a plant used in traditional
Mexican medicine, as a topical treatment for onychomycosis [27]. Results showed AP 10% lacquer
to be equivalent to ciclopirox 8% lacquer in terms of effectiveness against onychomycosis [27],
and a follow-up trial showed that higher concentrations of AP can improve patient outcomes [28].
Natural Coniferous Resin (NCR) lacquer showed a mycological cure rate of 65% in a preliminary
observational study [29], but only 13% in a randomised controlled trial. The clinical trial showed nine
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months of daily-applied NCR lacquer to be about as effective as weekly-applied amorolfine 5% lacquer,
but less effective than three months of once-daily oral terbinafine (250 mg) [30].
Recent pilot studies suggest potential for other natural compounds as therapeutic options for
onychomycosis. For example, propolis, an adhesive resinous compound produced by honeybees to seal
and protect their hives from pathogenic agents, exhibits significant antifungal and anti-biofilm activities
in vitro [31]. A pilot study assessing treatment of onychomycosis with topical ethanol propolis extract
for six months showed complete mycological and clinical cure in 56.3% (n = 16), with no adverse events
reported [31]. The over-the-counter topical cough suppressant Vicks VapoRub® also showed some
effectiveness against onychomycosis in a small-scale uncontrolled pilot study (n = 18; mycological cure
rate 27.8%; partial/complete clinical cure rate 55.6%/27.8%) [32]. This product contains a combination
of active and inactive ingredients, including camphor, eucalyptus oil, menthol and thymol, that have
shown in-vitro activity against dermatophytes. It has been suggested that Vicks VapoRub® may be a
suitable onychomycosis treatment for people living with HIV due to its low cost, minimal side effects
and compatibility with antiretroviral medications [33].
Further large well-designed randomised controlled trials are necessary to determine the efficacy
of natural treatments and make formal recommendations as to their use in onychomycosis.
Table 1. Clinical trials investigating natural therapies against onychomycosis.
Study Patients and Treatment Outcomes Treatment Comparisons
and Adverse Events (AE)
Buck et al. 1994 [34]
Randomised,
double-blind trial
117 pts with DLSO.
Tea tree oil (TTO) 100% (n = 64)
Clotrimazole (CL) 1% solution (n = 53)
Applied twice daily for 6 months
Mycologic cure TTO 18%
Clinical assessment TTO 60%
Patient assessment TTO 56%
Mycologic cure CL 11%
Clinical assessment CL 61%
Patient assessment CL 55%
No statistical differences
between treatments
Most common AE were
erythema and irritation
(7.8% TTO)
Syed et al. 1999 [35]
Randomised,
double-blind,
placebo-controlled trial
60 pts with DLSO
Butenafine hydrochloride (BH) 2%
and TTO 5% cream (n = 40)
Tea tree oil 5% cream (n = 20)
Applied three times daily for 8 weeks,
with nails debrided between weeks 4
and 6. Final follow up at 36 weeks
Complete cure BH + TTO
80%
Complete cure TTO 0%
BH + TTO was statistically
superior (p < 0.0001), and
mean time to complete
healing was 29 weeks
No AE in TTO group. Mild
skin inflammation in 4/40
pts in active BH + TTO
group
Auvinen et al. 2015 [30]
Prospective, randomised,
controlled,
investigator-blinded trial
73 pts with toenail
onychomycosisNatural Coniferous
Resin (NCR) lacquer (n = 23)
Applied once daily for 9 months
Amorolfine (A) 5% lacquer (n= 25)
Applied once weekly for 9 months
Oral terbinafine (T) 250 mg (n= 25)
Taken once daily for 3 months
Mycologic cure NCR 13%
Partial cure NCR 30%
Complete cure NCR 0%
Mycologic cure A 8%
Partial cure A 28%
Complete cure A 0%
Mycologic cure T 56%
Partial cure T 36%
Complete cure T 16%
At 10 months follow up, oral
T was significantly superior
to NCR and A in terms of
mycologic cure and clinical
outcomeNo AE in NCR or A
groups. 2 pts with diarrhoea
and rash in T group
Romero-Cerecero et al.
2008 [27]
Randomised, controlled,
double-blind trial
110 pts with toenail onychomycosis
Ageratina pichinchensis (AP) 10% lacquer
(n = 55)
Ciclopirox (CL) 8% lacquer (n = 55)
Applied once every three days for 4
weeks, twice a week for 4 weeks, then
once a week for 16 weeks. Lacquer
removed weekly
Clinical effectiveness AP
71.1%
Mycologic cure AP 59.1%
Treatment compliance 95.9%
Clinical effectiveness CL
80.9%
Mycologic cure CL 63.8%
Treatment compliance 100%
No statistical difference
between treatments
No severe AE reported
Romero-Cerecero et al.
2009 [28]
Randomised
double-blind trial
122 pts with DLSO
AP 12.6% lacquer (n = 62)
AP 16.8% lacquer (n = 60)
Applied once daily for 6 months
Clinical
effectiveness/complete cure
12.6% AP 67.2%
Clinical
effectiveness/complete cure
16.8% AP 79.1%
(no clinical manifestation in
toenails, considered healthy)
The 16.8% AP lacquer
formulation possessed a
higher effectiveness than the
12.6% AP lacquer
formulation (p = 0.01)No AE
reported
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Table 1. Cont.
Study Patients and Treatment Outcomes Treatment Comparisons
and Adverse Events (AE)
Menéndez et al. 2011 [36]
Randomised, controlled,
single-blind trial
400 pts with onychomycosis
OLEOZON®, ozonized sunflower oil *
(OSO) (n = 200)
Ketoconazole cream (KC) 2% (n = 200)
Applied twice daily for 3 months, with
filing and massage of affected nails
upon treatment application
Complete cure OSO 90.5%
Improvement OSO 9.5%
Complete cure KC 13.5%
Improvement KC 27.5%
After 3 months, OSO was
more effective compared to
KC (p < 0.00001)
At 1 year follow up, relapse
had occurred in 2.8% of
cured pts in OSO group and
37.0% of cured pts in KC
groupNo AE reported
Parekh et al. 2017 [37]
Randomized,
placebo-controlled,
double-blind,
parallel trial
28 pts with severe tinea (n = 18) or
onychomycosis (n = 10)
Calmagen® * cream or lotion (C) (n = 14)
Placebo (P) (n = 14)
Applied for 12 weeks
Mycologic cure C (13/14)
92.8%
Clinical cure C (14/14) 100%
Mycologic cure P (0/14) 0%
Clinical cure P (0/14) 0%
There was a significant
difference in mycologic cure
rate between both arms
(p < 0.0001)
No AE reported
DLSO = Distal lateral subungual onychomycosis; pts = patients; * with active ingredient AMYCOT®, a bioactive
extract derived from Arthospira maxima (Spirulina); adapted from studies reviewed by Halteh et al. [19].
5. Physical Treatments
Photodynamic therapy (PDT), plasma therapy and laser treatments are physical therapies that
have recently gained traction in the treatment of onychomycosis following the success of in-vitro
studies [10]. In PDT, light within a defined narrow spectrum is used to excite a photosensitising agent
applied directly to the target area and absorbed by the target organism, resulting in the formation of
reactive oxygen species that selectively destroy infected tissue [38]. Photosensitising agents currently
being investigated for onychomycosis treatment include the protoporphyrins aminolevulinic acid
and methyl-aminolevulinate, the haematoporphyrin derivative Photogem®, and rose bengal and
methylene blue dyes [21,39,40]. Studies investigating PDT to treat onychomycosis in vivo are still
largely limited to case reports, though a few small clinical trials have been performed [40].
A 2016 systematic review of five in-vitro and 12 in-vivo studies (mostly case reports and
unrandomised human trials) suggested that PDT may be able to provide a therapeutic benefit for
onychomycosis, with minimal (and no systemic) side effects [21]. Reported side effects (mild pain,
burning, erythema, oedema and blistering) were well tolerated and resolved within a few days. A 2014
randomised clinical trial assessing the efficacy of biweekly PTD showed a clinical cure rate of 90%
at six months (and 80% at 12 months) in 40 patients with toenail onychomycosis [41]. Affected nails
were treated for six months with 2% methylene blue and irradiated with noncoherent red light from an
LED device (630 nm, 18 J/cm2). Those in the comparative group receiving oral fluconazole responded
poorly, while the PDT treatment was effective and well tolerated. While outcomes of early trials
have been promising, further investigation is needed to confirm the efficacy and safety of PDT in
treating onychomycosis.
An important concern with PDT is the requirement for frequent and lengthy clinic visits (up to
several hours each), which may compromise patient compliance. Patients may need to attend up to
12 treatment sessions across six months, compared to only one or two doctor’s appointments while
undergoing oral or topical therapy [40]. Also, successful treatment appears to require pretreatment of
the affected area to improve penetration of the photosensitising agent into the nail plate. Studies to
date have employed pretreatment methods including application of urea ointment to soften the nail,
microabrasion or even complete removal of the nail plate [21].
Another physical treatment being investigated for onychomycosis is plasma therapy,
which involves applying nonthermal plasma to the infected nail surface. Pulses of strong electric field
are used to generate the plasma which ionizes surrounding air molecules to produce the antifungals
ozone, nitric oxide and hydroxyl radicals [10]. Nonthermal plasma has exhibited antifungal activity
in vitro [42,43], and a 2017 pilot study on a plasma device to treat onychomycosis (n = 19) showed the
treatment to be safe and effective, yielding a clinical cure of 53.8% and mycological cure of 15.4% [44].
Plasma therapy has similar advantages to PDT in that it is noninvasive, compatible with comorbidities
J. Fungi 2018, 4, 87 6 of 10
and does not interact with other drugs. Larger-scale trials are required to determine whether plasma
therapy can successfully treat onychomycosis in practice.
Laser therapy is a nonpharmacologic treatment thought to induce fungicidal activity through a
photothermal effect on nail fungi using the principle of selective photothermolysis. The mechanism
of action is not yet well understood, but one theory is that laser energy is preferentially absorbed by
fungal mycelia in the affected tissue, resulting in a rapid elevation in temperature and fungal cell
death [45]. Lasers have received regulatory approvals from the US Food and Drug Administration
(FDA) and Australian Therapeutic Goods Administration (TGA) to treat fungal-infected nails [22,46].
However, as emphasised in a recent review by Gupta et al. [22], the FDA approval for laser treatment
of onychomycosis restricts its use to aesthetic endpoints (for “the temporary increase of clear nail”)
rather than medical treatment goals (such as mycological or complete cure).
Various types of lasers have been investigated for use in the treatment of onychomycosis.
Those most extensively studied for this purpose are neodymium-doped yttrium aluminium garnet
(Nd:YAG) laser devices [47], which can be modified to operate in continuous, long-pulsed, Q-switched
or potassium titanyl phosphate modes. Nd:YAG lasers are typically used to emit a 1064-nm wavelength,
though both shorter and longer wavelengths are available. Onychomycosis has also been treated with
fractional carbon dioxide lasers, diode lasers and erbium:glass lasers [47]. Cost is a major factor when
considering laser and light treatments as they are not typically covered by health insurance plans.
As such, treatments can cost from US$400 to US$1200 per session [48], compared to only $10 for a
12-week course of terbinafine (or $53 if the cost of liver function tests is included) [49].
Recent reviews on laser treatment of onychomycosis have concluded that the evidence for its
effectiveness is limited and of poor methodological quality [22,50,51]. Current findings are largely
based on studies with small sample sizes, differing definitions for outcome measures and a lack of
control groups. A major point of difference between studies is that some evaluate endpoints using
patients as the unit of analysis with one target toenail, while others use nails as the unit of analysis and
include multiple nails per person, potentially resulting in overestimation of treatment efficacy [22].
In their 2017 review of 21 studies, Gupta and Versteeg [22] found that laser therapy resulted in clinical
improvement in 36% of patients (based on five studies) and 67% of nails (based on nine studies),
but clinical cure (100% clear nail) in only 13% of patients/nails (based on two/six studies). Mycological
cure, a standard endpoint of treatment, occurred on average in 11% of patients (two studies) and 63%
of nails (three studies). Therefore, laser therapies may be somewhat effective in achieving cosmetic
endpoints in onychomycosis, but they do not equal or exceed the efficacy of current topical and oral
treatments in terms of achieving medical endpoints [22]. Based on the present evidence, lasers should
not be considered an effective first-line therapy for onychomycosis.
6. Combination Therapy
Combining onychomycosis treatment options can increase their efficacy and improve patient
outcomes, possibly due to synergy, differing mechanisms of action and restricting the effect of fungal
resistance [52]. In their 2017 review, Gupta and colleagues [52] summarised studies combining oral
and/or topical drugs for onychomycosis, revealing that combination therapy is sometimes (though not
always) more effective than monotherapy. Most studies combined oral terbinafine or itraconazole with
topical amorolfine 5%, ciclopirox 8% or terbinafine.
Many combination therapies for onychomycosis are based on improving drug delivery to
the infected nail via adjunct physical, mechanical or chemical treatments, including nail filing,
nail trimming, debridement, chemical avulsion and the drilling of small holes into the nail plate
(microporation) [52]. A promising emerging adjunct treatment is iontophoresis, which may be
combined with topical therapies to improve their effectiveness. The method involves passing a
small electrical current through a biological membrane that allows transportation of hydrophobic
or charged drug molecules. Early investigations indicate that terbinafine can be delivered at higher
concentrations using iontophoresis, improving the ability of the drug to eliminate fungi [53,54].
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Recent studies have looked at combining topical therapies and laser treatments to improve drug
penetration into the nail. One randomised clinical trial evaluated the clinical efficacy and safety of
weekly applications of amorolfine 5% lacquer, either as a monotherapy (n = 64) or in combination with
four 1064-nm Nd:YAG laser treatments (n = 64) over 16 weeks [55]. At 16 weeks, the combined therapy
group showed a significantly higher cumulative cure rate than the control group (71.9% vs. 20.3%,
p < 0.0001). Combined therapy was generally well tolerated (with patients experiencing transient
discomfort), showing potential for use as an alternative treatment for patients with contraindications
to systemic antifungal agents. Other small-scale pilot studies have shown similarly promising results
for twice-weekly amorolfine 5% lacquer combined with six fractional erbium yttrium aluminum
garnet (Er:YAG) laser treatments [56], and daily amorolfine cream combined with three fractional
carbon-dioxide laser treatments (no control group) [57].
Preliminary investigations of laser therapy plus oral medications to treat onychomycosis have
shown that long-pulsed 1064-nm Nd:YAG laser treatments, combined with oral terbinafine for
12 weeks, resulted in significantly higher mycological and clinical clearance rates than either treatment
alone [58], while a combination of similar laser treatments with oral itraconazole was statistically
superior to the itraconazole alone only when the onychomycosis was classified as ‘severe’ rather than
‘mild or moderate’ [59]. Further controlled studies are required to evaluate whether these combination
therapies have sufficient merit to recommend in practice.
The limited safety profile of oral antifungals, poor nail penetration of onychomycosis drugs,
and mediocre therapeutic efficacies of conventional treatment modalities signal the need for new
treatment options and therapeutic inventions. Emerging treatments include new topical, photodynamic
and laser therapies, and combination therapies appear to hold promise for improving patient outcomes.
It is likely that in the imminent future, additional topical agents, including those which are currently
approved for other superficial fungal infections (such as tinea pedis), will become available to
onychomycosis patients. Preliminary trials on natural topical treatments have revealed some promising
agents which may be useful as safe alternatives to current therapies for the long-term management of
onychomycosis, especially in patient populations where standard oral therapy is limited. However,
the current evidence is insufficient to make broad clinical recommendations.
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